Cambridge Healthtech Institute's
Genome Tri-Conference
The Fairmont Hotel —San Francisco, California
February 9-15, 1998
The first two conferences highlight key technical progress and
its application in the development of new therapeutic understanding
and novel compounds. The third program showcases emerging genomics
companies and is designed to facilitate evaluation and networking.
Look closely at each meeting and decide to attend one, a pair, or
all three. Our goal is to make the entire week work for you!
Special Multi-Conference Rates Available
Contact us directly, or visit the News/Features section of our
website at http://www.healthtech.com/conferences/ for more information.
Fifth Annual
HUMAN GENOME PROJECT: Commercial Implications
February 9-11, 1998
Corporate Support Provided by: PE Applied Biosystems
As the Human Genome Project gears up into the sequencing
phase, the expectations for translating such data into
valuable information increase. While automated gel-based
sequencing remains the workhorse of this effort, newer
approaches have moved much closer to becoming practical.
Much greater emphasis is also being placed on software
for analyzing sequences and the creation of gene expression
libraries and databases. Such databases, in combination
with analysis of gene function, will play a key role in the
identification of novel targets for diagnostic and therapeutic
applications. The third day of this meeting will again feature
case studies of genomic data-based drug development efforts.
This meeting has become established as a key forum for academic
and commercial researchers to discuss and find out about the
latest technology and applied developments in the genomics
field.
Scientific Advisors
Dr. Roger Brent, Massachusetts General Hospital and
Harvard Medical School
Dr. Carol A. Dahl, National Cancer Institute
Dr. Mark Schena, Stanford University Medical Center
Dr. Robert L. Strausberg, National Cancer Institute
Overview
Keynote Presentations
A Toothpick-Wielding Microbial Geneticist Looks at the Future
Dr. Ira Herskowitz, University of California, San Francisco
Perspective on Where Genomics Is Heading
Dr. Randy Scott, Incyte Pharmaceuticals
The Hammer and the Handshake: Coordinate Approaches for Obtaining
Meaningful Intellectual Property Protection and Operating in a
Patent-Protected Environment in Genomics
Dr. Kathleen Madden Williams, Banner & Witcoff Ltd.
Panel on Prospects for Genomic Investments
Dr. Brian Atwood, Brentwood Venture Capital
Dr. Jean-François Formela, Atlas Venture
Dr. Hugh Reinhoff, Abingworth Venture Management, Inc.
Strategic Use of Genomic Information
Identifying Genes and Other Important Sequence Elements Using ESTs
and Comparative Sequencing Efforts
Dr. Richard Wilson, Washington University
Full-Length cDNA, an Entry to Function Determination
Dr. C. Thomas Caskey, Merck Research Laboratories
Cancer Genome Anatomy Project
Dr. Robert L. Strausberg
The Use of Information from Functional Genomics and Pharmacology
in the Discovery of New Approaches to the Treatment of Human Disease
Dr. Gordon Baxter, Pharmagene Laboratories Ltd.
Pharmacogenomics and Drug Prescription
Dr. Marta Blumenfeld, Genset
Comprehensive Molecular Analysis Tools
Keynote Presentation
Assessing the Human Genome Project at the Halfway Point
Dr. Francis S. Collins, National Human Genome Research
Institute
Moving Beyond the Sequence: Protein-Based Tools for Assigning
Gene and Allele Function
Dr. Roger Brent
ARAKIS, a Powerful Technology for Genome Sequencing and
Clinical Diagnostic
Dr. Hartmut Voss, Lion Bioscience AG
Automation for Cost Reduction in Large-Scale DNA Sequencing
Dr. Andre Marziali, Stanford DNA Sequencing and Technology
Development Center
Integrating the Complementary Information from High-Throughput
Sequencing and DNA Microarray Analysis
Dr. David Barker, Molecular Dynamics
SELDI: Connecting Gene Expression Monitoring with Protein
Function and Drug Discovery
Dr. William Hutchens, Ciphergen Biosystems
Parallel Analysis with Biological Chips
Accelerating Drug Discovery with Gene Expression Microarrays
Dr. Dari Shalon, Synteni Inc.
Chip-Based Expression Analysis: Linking Sequence and Function
Dr. Mark Schena
Genome Analysis Using SBH Tools
Dr. Radoje Drmanac, Hyseq, Inc.
cDNA Arrays for the Masses
Dr. Paul Siebert, Clontech Inc.
Integrated Microelectronic Systems for Genomic Research and
Diagnostic Applications
Dr. Michael J. Heller, Nanogen, Inc.
Methods for Identification of Lead Genes
The First Gene Targets from a Novel Academic-Industry Liaison
Dr. Richard E. Kouri, VIMRX Genomics, Inc.
Using Viral Signposts to Zoom In on Therapeutically Important Genes
Dr. Subha Srinivasan, Immunex Corporation
Leveraging Bioinformatics and a Gene Expression Technology
Platform to Accelerate Lead Discovery
Dr. Keith Elliston, Gene Logic, Inc.
Applications of Genomics in Target Identification and Lead
Development
Dr. Douglas R. Smith, Genome Therapeutics Corporation
Aptameric Antagonists as Target Validation Tools
Dr. Barry Polisky, NeXstar Pharmaceuticals
Genomic Drug Discovery
Novel Approaches to Drug Discovery Research
Dr. Lee E. Babiss, Glaxo Wellcome Research and Development
New Approaches to Target Identification in Mouse and Man
Dr. David Galas, Darwin Molecular Corporation
Pyrrole-Imidazole Polyamides as Specific Inhibitors of Gene
Transcription in Vitro and in Vivo
Dr. Joel Gottesfeld, Scripps Research Institute
DiscoverEase™ Program for Identifying Secreted Proteins
Dr. Sharan Pagano, Genetics Institute
Second Annual
GENE FUNCTIONAL ANALYSIS
February 12-13, 1998
As the complete genomes of the first model organisms become
available, it is now possible to explore how well such data
can be interpreted in terms of functional analysis. The sheer
volume of genetic sequence is going to require a paradigm
shift from laborious determination of function for one gene
at a time to high-throughput approaches that can automatically
assist in such efforts, via homolgy and cross-species
comparisons. The use of libraries of mutants or knockouts
also represents a key approach toward faster analysis.
Efforts to determine function of gene sequences and relate
them to genetic pathways and roles in disease will be key for
exploiting genetic information for medicinal purposes.
Scientific Advisors
Dr. Doug Bassett, Fred Hutchinson Cancer Research Center
Dr. Roger Brent, Massachusetts General Hospital and Harvard
Medical School
Dr. Edward M. Rubin, University of California, Berkeley
Keynote Presentation
Dr. Patrick O. Brown, Stanford University School of Medicine
Functional Genomics
Model Organisms and Human Disease
Dr. Doug Bassett
Genome Diversity and Functional Genomics
Dr. Mark W. Bodmer, Hexagen
Gene Function Analysis by the Integration of Phenotypic and
Genotypic Databases
Dr. Dirk Gewert, Gemini Biochemical Research
Identification of Critical Genes in Disease Pathways
Dr. Lynne Zydowsky, Exelixis Pharmaceuticals
Large-Scale Functional Analysis of the S. Cerevisiae Genome
Dr. Petra Ross-Macdonald, Yale University
Gene Expression
Using Protein Networks and Peptide Aptamers to Elucidate
Pathways, Genes, and Alleles
Dr. Roger Brent
Functional Analysis in Silico
Dr. Reinhard Schneider, Lion Bioscience AG
CodeSig™ Technology for Discovery of Variation in Gene Expression
Dr. Gualberto Ruano, Genaissance Pharmaceuticals
Finding Genes Across Species
Dr. Pavel Pevzner, University of Southern California
Linking Genome to Metabolome by High-Throughput Mass
Spectrometric Genetic Profiling: Novel Strategy to Unravel
Gene Function
Dr. Adelbert A. Roscher, GeneValid GmbH
Genomic Analysis of C. Elegans
Dr. Erik Sonnhammer, National Center for Biotechnology
Information (invited)
Genome Manipulation
Radiation-Induced Deletions in Mice Using ES Cells
Dr. John Schimenti, Jackson Laboratory
Exploiting the Mouse to Sift Sequence for Function
Dr. Edward M. Rubin
OmniBank: An Engine of Drug Discovery
Dr. Arthur T. Sands, Lexicon Genetics
Streamlined Approaches to Targeted Loss- and Gain-of-Function
Mouse Genetics
Dr. George Gaitanaris, National Cancer Institute
Chromophore-Assisted Laser Inactivation
Dr. Daniel Jay, Harvard University
